Oncologie

Taxol ® (paclitaxel) 225mg/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer

Proceedings of the American Society of Clinical Oncology 1996 Bonneterre J, Tubiana-Hulin M, Chollet Ph, Chevallier B, Fumoleau P, Kerbrat P, Vié B, Khayat D, Tubiana N, Lejeune C, Soler-Michel P, Soares JA, Pellae-Cosset B, Chazard M.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Risk Factors TFR CP-CML
Success stories - Oncologie - Facultatif

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients

Long-Term TKI Treatment Patterns
Success stories - Oncologie - Facultatif

Tyrosine Kinase Inhibitor (TKI) Treatment Patterns in 5,261 Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients in “Real-Life”

Use of Digital Health Technology to Enable Drug Development
Oncologie

Use of Digital Health Technology to Enable Drug Development